Biogen CEO Michel Vounatsos’ 2021 pay dropped about $1 million from 2020. Still, the helmsman got off light considering the incredibly rocky rollout of Biogen’s controversial Alzheimer’s disease drug, Aduhelm.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,